These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 10672264)
21. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Wright CI; Geula C; Mesulam MM Ann Neurol; 1993 Sep; 34(3):373-84. PubMed ID: 8363355 [TBL] [Abstract][Full Text] [Related]
22. The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization. Desgranges B; Baron JC; de la Sayette V; Petit-Taboué MC; Benali K; Landeau B; Lechevalier B; Eustache F Brain; 1998 Apr; 121 ( Pt 4)():611-31. PubMed ID: 9577389 [TBL] [Abstract][Full Text] [Related]
23. Positron emission tomography in patients with clinically diagnosed Alzheimer's disease. McGeer PL; Kamo H; Harrop R; Li DK; Tuokko H; McGeer EG; Adam MJ; Ammann W; Beattie BL; Calne DB CMAJ; 1986 Mar; 134(6):597-607. PubMed ID: 3512063 [TBL] [Abstract][Full Text] [Related]
24. Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. Ishii K; Willoch F; Minoshima S; Drzezga A; Ficaro EP; Cross DJ; Kuhl DE; Schwaiger M J Nucl Med; 2001 Apr; 42(4):548-57. PubMed ID: 11337540 [TBL] [Abstract][Full Text] [Related]
25. Multimodal Discrimination of Alzheimer's Disease Based on Regional Cortical Atrophy and Hypometabolism. Yun HJ; Kwak K; Lee JM; PLoS One; 2015; 10(6):e0129250. PubMed ID: 26061669 [TBL] [Abstract][Full Text] [Related]
26. Immunolocalization and redistribution of the FAC1 protein in Alzheimer's disease. Schoonover S; Davies P; Bowser R J Neuropathol Exp Neurol; 1996 Apr; 55(4):444-55. PubMed ID: 8786404 [TBL] [Abstract][Full Text] [Related]
27. Preferential metabolic involvement of visual cortical areas in a subtype of Alzheimer's disease: clinical implications. Pietrini P; Furey ML; Graff-Radford N; Freo U; Alexander GE; Grady CL; Dani A; Mentis MJ; Schapiro MB Am J Psychiatry; 1996 Oct; 153(10):1261-8. PubMed ID: 8831432 [TBL] [Abstract][Full Text] [Related]
28. In vivo imaging of region and cell type specific neocortical neurodegeneration in Alzheimer's disease. Perspectives of MRI derived corpus callosum measurement for mapping disease progression and effects of therapy. Evidence from studies with MRI, EEG and PET. Hampel H; Teipel SJ; Alexander GE; Pogarell O; Rapoport SI; Möller HJ J Neural Transm (Vienna); 2002 May; 109(5-6):837-55. PubMed ID: 12111472 [TBL] [Abstract][Full Text] [Related]
29. Spatial patterns of atrophy, hypometabolism, and amyloid deposition in Alzheimer's disease correspond to dissociable functional brain networks. Grothe MJ; Teipel SJ; Hum Brain Mapp; 2016 Jan; 37(1):35-53. PubMed ID: 26441321 [TBL] [Abstract][Full Text] [Related]
31. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum. Tosun D; Schuff N; Jagust W; Weiner MW; Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336 [TBL] [Abstract][Full Text] [Related]
32. Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer's disease. Fan Z; Okello AA; Brooks DJ; Edison P Brain; 2015 Dec; 138(Pt 12):3685-98. PubMed ID: 26510952 [TBL] [Abstract][Full Text] [Related]
33. Greater metabolic rate decreases in hippocampal formation and proisocortex than in neocortex in Alzheimer's disease. Stein DJ; Buchsbaum MS; Hof PR; Siegel BV; Shihabuddin L Neuropsychobiology; 1998; 37(1):10-9. PubMed ID: 9438267 [TBL] [Abstract][Full Text] [Related]
34. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients. Montine TJ; Markesbery WR; Zackert W; Sanchez SC; Roberts LJ; Morrow JD Am J Pathol; 1999 Sep; 155(3):863-8. PubMed ID: 10487843 [TBL] [Abstract][Full Text] [Related]
35. Cortical metabolism, acetylcholinesterase staining and pathological changes in Alzheimer's disease. McGeer EG; McGeer PL; Kamo H; Tago H; Harrop R Can J Neurol Sci; 1986 Nov; 13(4 Suppl):511-6. PubMed ID: 2431752 [TBL] [Abstract][Full Text] [Related]
36. Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. Ishii K; Sasaki M; Kitagaki H; Yamaji S; Sakamoto S; Matsuda K; Mori E J Nucl Med; 1997 Jun; 38(6):925-8. PubMed ID: 9189143 [TBL] [Abstract][Full Text] [Related]
37. PDGF is associated with neuronal and glial alterations of Alzheimer's disease. Masliah E; Mallory M; Alford M; Deteresa R; Saitoh T Neurobiol Aging; 1995; 16(4):549-56. PubMed ID: 8544904 [TBL] [Abstract][Full Text] [Related]
38. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia. Yew B; Nation DA; Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149 [TBL] [Abstract][Full Text] [Related]
39. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Minoshima S; Giordani B; Berent S; Frey KA; Foster NL; Kuhl DE Ann Neurol; 1997 Jul; 42(1):85-94. PubMed ID: 9225689 [TBL] [Abstract][Full Text] [Related]